Although breakthroughs in immune checkpoint blockade therapy have been achieved in recent years, in many cases, the blockade of a single checkpoint (CTLA-4, PD-1, TIGIT, etc.)cannot achieve the desired therapeutic effects [62,63], which may be related to mutual modulation by multiple immune checkpoint receptors or ligands in the tumor microenvironment. The gene discussed is TIGIT; the disease is neoplasm.